Fig. 1Abdominal computed tomography (A) and magnetic resonance imaging of the liver (B) at admission showed a ~10 cm mass in the right lobe of the liver that had a high signal intensity on T2-weighted images and early arterial enhancement and delayed washout on dynamic contrast-enhanced images. Also, the hepatic mass had a low signal intensity on the hepatobiliary phase and high cellularity on the diffusion phase (white arrows).
Fig. 2An 131I-metaiodobenzylguanidine scan showed increased uptake in the right adrenal gland bed and adjacent liver parenchyma.
Fig. 3Transcatheter arterial chemoembolization (TACE). (A) The hepatic mass was stained in the celiac angiogram. An emulsion of 10 mL of lipiodol and 50 mg of doxorubicin was injected. (B) The tumor was well lipiodolized, as observed by post-TACE imaging. Abdominal computed tomography scans taken (C) 2 weeks and (D) 7 months after TACE revealed partial lipiodol uptake and necrotic changes in the center of the liver mass. The size of the mass (white arrow) had decreased to 8.3 cm.
Fig. 4Vital signs during the first 6 days after transcatheter arterial chemoembolization (TACE). A hypertensive crisis was observed immediately after TACE. The arrows indicate the time of TACE. DBP, diastolic blood pressure; SBP, systolic blood pressure.
Fig. 5Relative estimates of pre- and post-transcatheter arterial chemoembolization (TACE) serum catecholamine levels. Marked decreases in (A) norepinephrine and (B) normetanephrine levels were observed 2 weeks after TACE. E, serum epinephrine (pg/mL); NE, norepinephrine (pg/mL); M, metanephrine (nmol/L); NM, normetanephrine (nmol/L).